Q3 2025 Clinical Laserthermia Systems AB Earnings Call Transcript

Nov 14, 2025 / 09:00 AM GMT

Release Date Price: €0.741 (-13.64%)

Transcript

Key Points

Positve

Clinical Laserthermia Systems AB (FRA:LS60) received FDA clearance for expanded labeling, allowing installations on both 3 Tesla and 1.5 Tesla MRI scanners, effectively doubling the addressable neurosurgery market in the US.
The company successfully completed a financing package, raising a total of $37 million, which supports its growth strategy.
Clinical studies showed positive results, with increased median survival for patients treated with the CLS Prism system compared to traditional surgery.
The company maintained a gross margin well above the 60% target in its neurobusiness segment.
Operating expenses were reduced by more than the targeted 30% compared to the previous year, demonstrating effective cost control.

Negative

Q3 revenue decreased to 2.8 million SEK, a reduction compared to the same period last year, primarily due to timing of deliveries and lower sales in the urology segment.
The late arrival of FDA clearance impacted expected sales in Q3, shifting potential revenue to Q4 and beyond.
The company does not reaffirm high-end double-digit growth for 2025, indicating potential challenges in achieving aggressive growth targets.
There is ongoing volatility in sales, particularly in consumables, which may affect financial predictability.
Despite a strong financial position, the company remains cautious about additional cash needs to reach cash flow positivity by 2026.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CLSRb.ST - Clinical Laserthermia Systems AB
Q3 2025 Clinical Laserthermia Systems AB Earnings Call
Nov 14, 2025 / 09:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
It includes both the 3 Tesla and a 1.5 Tesla MR image guidance, and with that, we're doubling the total adjustment market in neurosurgery in the US.

We also had positive results that was, published, early October, from the clinical study that was conducted by a team at Ska University Hospital that was presented at the CNS annual meeting in Los Angeles. I will get back to some of the details of that, later in our presentation.

One interesting, spin-off of that was that the TV4 news will have a feature, will have, will, feature a short segment, on the treatments of brain tumors, also then highlighting the Neuroit and the CLS sponsored study at, Ska University Hospital. That will happen

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.